Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
on health and the environment. Ongoing research is conducted with both vertebrate and invertebrate model organisms and in vitro systems using various current methodologies. Research is carried out within two
-
synaptic assessment in in vivo and in vitro models. We are looking for a highly motivated individual to join a collaborative, diverse, and creative research team. Experience in molecular biology, data
-
tools, and in vitro cell culture facilities Participation in (inter)national conferences, training programs, and skills-development workshops Opportunities for international collaboration and research
-
, interdisciplinary research project Access to state-of-the-art plasma systems, surface characterization tools, and in vitro cell culture facilities Participation in (inter)national conferences, training programs, and
-
project focused on developing and applying a CTC-on-CAM platform for functional profiling of circulating tumor cells (CTCs) in lung cancer. The project integrates CTC isolation, in vitro handling
-
tissue culture. Execute in vitro therapeutic studies, including proliferation and metabolic luminescence assays. Perform fluorescence- and magnetic-activated cell sorting (FACS and MACS). Generate high
-
design, consulting with other researchers, analysing data, and presenting and reporting results. You will primarily conduct in vitro experiments using molecular biology and gene-editing techniques, as
-
in vitro, in vivo, and in silico methods, ideally integrating clinical or translational data. Key deliverables of the project are: Identification and functional validation of specific microcircuit(s
-
) to generate primate models for key gene functions and intractable diseases; 4) to reconstitute key human cell lineages and tissues in vitro and validate their properties based on integrative information; and 5
-
cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs. Leukemia 2024 https